Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST
Inhibikase Therapeutics Employees
Inhibikase Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 19 or 118.75% compared to the previous year. That makes Inhibikase Therapeutics the 36,541st largest employer in the world and 5,018th in the United States.
Employees
35
Change (1Y)
19
Growth (1Y)
118.75%
Revenue / Employee
n/a
Profits / Employee
-$1,976,402
Market Cap
277.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 19 | 118.75% | 35 | 0 |
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Nautilus Biotechnology | 128 |
| Scribe Therapeutics | 82 |
| Agenus | 81 |
| Century Therapeutics | 78 |
| Larimar Therapeutics | 71 |
| AgomAb Therapeutics NV | 62 |
| PepGen | 57 |
IKT News
- 2 days ago - Inhibikase Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 8 days ago - Inhibikase Therapeutics Earnings release: Q3 2026 - Filings
- 8 days ago - Inhibikase Therapeutics Quarterly report: Q3 2026 - Filings
- 8 days ago - Inhibikase Therapeutics Slides: Corporate presentation - Filings
- 22 days ago - Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 - GlobeNewsWire
- 4 weeks ago - Inhibikase Therapeutics appoints Kailera CMO Scott Wasserman to board - TheFly
- 4 weeks ago - Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors - GlobeNewsWire